From Oct. 18- 23, MAPS Executive Director Rick Doblin, Ph.D. will be in Israel and Jordan, where he will meet with Clinical Investigator Moshe Kotler, M.D., of our Israeli study, to discuss starting a new Israel MDMA/PTSD study. Meanwhile, MAPS’ clinical research team is finishing an abbreviated report about our initial Israeli MDMA/PTSD study to submit to the FDA and the Israeli Ministry of Health. Five subjects were enrolled, of which four completed treatment. There were no safety problems for any subjects. There were too few subjects to conduct a statistical analysis, nevertheless, the report will be a detailed review of the study with all the raw data summarized. Sponsoring the project was an excellent learning experience both for us and for the Israeli team. We feel confident we can conduct a new study in a rigorous manner.